Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3581609 | 0.82 | ALDH1A1 (0.53) | PKMALDH1A1ESR1KDM4EAPOBEC3G | |
| SCHEMBL14058258 | 0.79 | PKM (0.51) | PKMALDH1A1ESR1KDM4EAPOBEC3G | |
| SCHEMBL2425157 | 0.79 | NR1I2 (0.45) | APOBEC3GKMT2ACA12CA9LMNA | |
| SCHEMBL812682 | 0.76 | PKM (0.79) | PKMALDH1A1ESR1APOBEC3GKMT2A | |
| SCHEMBL3828857 | 0.73 | ALDH1A1 (0.80) | PKMALDH1A1ESR1KDM4EAPOBEC3G | |
| SCHEMBL28608175 | 0.72 | KDM4E (0.30) | ALDH1A1KDM4EMAPTTDP1 | |
| SCHEMBL1851448 | 0.70 | DHFR (0.37) | KMT2AMEN1 | |
| SCHEMBL6945191 | 0.70 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL9765894 | 0.70 | — | — | |
| SCHEMBL28924360 | 0.70 | NPSR1 (0.30) | NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238691-B2 | Nucleic acids encoding antibodies to CCR2 | PFIZER INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20140342450-A1 | ANTIBODIES TO CCR2 | AMGEN FREMONT INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8481579-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| CN-101511800-B | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX INC | 2013-02-27 | — | — | CN | disclosed |
| CN-101511800-B | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX INC | 2013-02-27 | — | — | CN | disclosed |
| US-8153818-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-7718683-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| CN-101511800-A | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX INC (US) | 2009-08-19 | — | — | CN | disclosed |
| CN-101511800-A | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX INC (US) | 2009-08-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140342450-A1 | ANTIBODIES TO CCR2 | CCR2, CCR1, CCR5 | PKM 4617/4885ALDH1A1 2389/4885ESR1 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.